NCT01813344

Hyper-CVAD Treatment in Lymphoblastic Lymphoma

The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Ajou University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment outcome of hyper-CVAD in LBL has reported only in small number of patients from single institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based treatment in LBL.

Detailed description

We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment. After achievement of response, patients either underwent hematopoietic stem cell transplantation (HSCT) or consolidation with hyper-CVAD.

Conditions

• Lymphoblastic Lymphoma

Timeline

• Start date: 2012-01-01
• Primary completion: 2013-06-01
• First posted: 2013-03-19
• Last updated: 2013-03-19

Locations

1 site across 1 country: South Korea